Protective effect of carvedilol on oxidative stress induced by okadaic acid in N1E-115 cells

Pharmacological Research

Volumn 54, Issue 3, 2006, Pages 241-246

  Túnez, Isaac ^a   Collado, Juan A ^b   Medina, Francisco J ^a   Muñoz, M Carmen ^a   Gordillo, Rafael ^a   Sampedro, Concepción ^a   Moyano, María J ^a   Feijóo, Montserrat ^a   Muntané, Jordi ^b   Montilla, Pedro ^a  

^a Universidad de Cordoba   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Carvedilol; N1E 115 cell; Okadaic acid; Oxidative stress

Indexed keywords

CARBONYL DERIVATIVE; CARVEDILOL; CATALASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; LACTATE DEHYDROGENASE; OKADAIC ACID; SUPEROXIDE DISMUTASE;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CELL DAMAGE; CELL PROTECTION; CONTROLLED STUDY; DRUG EFFECT; INCUBATION TIME; LIPID PEROXIDATION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CARBAZOLES; CATALASE; CELL LINE, TUMOR; DRUG INTERACTIONS; GLUTATHIONE; GLUTATHIONE PEROXIDASE; L-LACTATE DEHYDROGENASE; LIPID PEROXIDATION; MELATONIN; MICE; NEUROBLASTOMA; OKADAIC ACID; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROPANOLAMINES; PROTEINS; SUPEROXIDE DISMUTASE;

EID: 33746365586     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2006.05.004     Document Type: Article

References (46)

1. Bialojan C., and Takai A. Inhibitory effect of a marine-sponge toxin, okadaic acid on protein phosphatases: specificity and kinetics. Biochem J 256 (1988) 283-290
2. Chiou J.Y., and Westhead E.W. Okadaic acid, a protein phosphate inhibitor, inhibits nerve growth factor-directed neurite outgrowth in PC12 cells. J Neurochem 59 (1992) 1963-1966
3. Arias C., Sharma N., Davies P., and Shafit-Zagardo B. Okadaic acid induces early changes in microtubule-associated protein 2 and tau phosphorylation prior to neurodegeneration in cultured cortical neurons. J Neurochem 61 (1993) 673-683
4. Dupont-Wallois L., Sautiere P.E., Cocquerelle C., Bailleul B., Delacourte A., and Caillet Boudin M.L. Shift from fetal-type to Alzheimer-type phosphorylated tau proteins in SKNSH-SY 5Y cells treated with okadaic acid. FEBS Lett 357 (1995) 197-201
5. Chen K.D., Lai M.T., Cho J.H., Chen L.Y., and Lai Y.K. Activation on p38 mitogen-activated protein kinase and mitochondrial Ca(2+)-mediated oxidative stress are essential for the enhanced expression of grp78 induced by the protein phosphatase inhibitors okadaic acid and calyculin A. J Cell Biochem 76 (2000) 1963-1966
6. Lee J., Hong H., Im J., Byun H., and Kim D. The formation of PHF-1 and SMI-31 positive dystrophic neuritis in rat hippocampus following acute injection of okadaic acid. Neurosci Lett 282 (2000) 49-52
7. Traore A., Ruíz S., Baudrimont I., Sanni A., Dano S.D., Guarigues J.F., et al. Combined effects of okadaic acid and cadmium on lipid peroxidation and DNA bases modifications (m5dC and 8-(OH)-dG) in Caco-2-cells. Arch Toxicol 74 (2000) 466-472
8. Nichols A.J., Gellai M., and Ruffolo Jr. R.R. Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol. Fundam Clin Pharmacol 5 (1991) 25-38
9. Feuerstein G.Z., and Ruffolo Jr. R.R. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur Heart J 16 (1995) 38-42
10. Dulin B., and Abraham W.T. Pharmacology of carvedilol. Am J Cardiol 93 (2004) 3B-6B
11. Feuerstein G., Yue T.L., Ma X., and Ruffolo Jr. R.R. Novel mechanisms in the treatment of heart failure: inhibition of oxygen radicals and apoptosis by carvedilol. Prog Cardiovasc Dis 41 (1998) 17-24
12. Calo L.A., Semplicini A., and Davis P.A. Antioxidant and antiinflammatory effect of carvedilol in mononuclear cells of hypertensive patients. Am J Med 118 (2005) 201-202
13. 2+-ATPase 2 gene transcription through modification of Sp1 binding. Biochem Biophys Res Commun 328 (2005) 116-124
14. Lysko P.G., Lyzko K.A., Yue T.L., Webb C.L., Gu J.L., and Feuerstein G. Neuroprotective effects of carvedilol, a new antihypertensive agent, in cultured rat cerebellar neurons and in gerbil global brain ischemia. Stroke 23 (1992) 1630-1635
15. Howlett D.R., George A.R., Owen D.E., Ward R.V., and Markwell R.E. Common structural features determine the effectiveness of carvedilol, daunomycin and rolitetracycline as inhibitors of Alzheimer β-amyloid fibril formation. Biochem J 343 Pt 2 (1999) 419-423
16. Suzuki Y., Tanaka M., Sohmiya M., Yoshida T., and Okamoto K. Antioxidant properties of carvedilol: inhibition of lipid peroxidation, protein oxidation and superoxide generation. Neurol Res 25 (2003) 749-753
17. Benítez-King G. PKC activation by melatonin modulates vimentin intermediate filament organization in N1E-115 cells. J Pineal Res 29 (2000) 8-14
18. Montilla-López P., Muñoz-Águeda M.C., Feijóo López M., Muñoz-Castañeda J.R., Bujalance-Arenas I., and Túnez-Fiñana I. Comparison of melatonin versus vitamin C on oxidative stress and antioxidant activity in Alzheimer's disease induced by okadaic acid in neuroblastoma cells. Eur J Pharmacol 451 (2002) 237-243
19. Benítez-King G., Túnez I., Bellón A., Ortiz G.G., and Antón-Tay F. Melatonin prevents cytoskeletal alterations and oxidative stress induced by okadaic acid in N1E-115 cells. Exp Neurol 182 (2003) 151-159
20. Levine R.L., Garland D., Olivier C.N., Amici A., Climent I., Lenz A.G., et al. Determination of carbonyl content in oxidatively modified proteins. Meth Enzymol 186 (1990) 464-478
21. Flohé L., and Gunzler W.A. Assays of glutathione peroxidase. Meth Enzymol 105 (1984) 114-121
22. Aebi H. Catalase in vitro. Meth Enzymol 105 (1984) 121-126
23. Taffs R., and Sitkovsky M. In vitro assays for mouse B and T lymphocyte function. In: Coligan J.E., Kruisbeek A.M., Margulies D.H., Shevach E.M., and Strober W. (Eds). Current protocols in immunology (1991), Greene Publishing and Wiley Interscience, New York 1-18
24. Cagnin A., Brooks D.J., Kennedy A.M., Gunn R.N., Myers R., Turkheimer F.E., et al. In-vivo measurement of activated microglia in dementia. Lancet 358 (2001) 461-467
25. Butterfield D.A., Castegna A., Lauderback C.M., and Drake J. Evidence that amyloid beta-peptide-induced peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol Aging 23 (2002) 655-664
26. Choi J., Malakowsky C.A., Talent J.M., Conrad C.C., Carroll C.A., Weintraub S.T., et al. Anti-apoptotic proteins are oxidized by abeta25-35 in Alzheimer's fibroblasts. Biochem Biophys Acta 1637 (2003) 4368-4374
27. Smith M.A., Hirai K., Hsiao K., Pappolla M.A., Harris P.L., Siedlak S.L., et al. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 70 (1998) 2212-2215
28. Pappolla M.A., Sos M., Omar R.A., Bick R.J., Hickson-Bick D.L.M., and Reiter R.J. Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer's amyloid peptide. J Neurosci 17 (1997) 1683-1690
29. Uchida K. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog Lipid Res 42 (2003) 318-343
30. Gómez-Ramos A., Smith M.A., Perry G., and Ávila J. Tau phosphorylation and assembly. Acta Neurobiol Exp 64 (2004) 33-39
31. Mattson M.P. Metal-catalyzed disruption of membrane protein and lipid signalling in the pathogenesis of neurodegenerative disorders. Ann NY Acad Sci 1012 (2004) 37-50
32. Arendt T., Holzer M., Brückner M.K., Janke C., and Gärtner U. The use of okadaic acid in vivo and the induction of molecular changes typical for Alzheimer's disease. Neuroscience 85 (1998) 1337-1340
33. Smith M.A., and Perry G. Free radical damage, iron, and Alzheimer's disease. J Neurol Sci 134 (1995) 92-94
34. Zhu X., Smith M.A., Perry G., and Aliev G. Mitochondrial failures in Alzheimer's disease. Am J Alzheimers Dis Other Demen 19 (2004) 345-352
35. Liu Q., Lee H.G., Honda K., Siedlak S.L., Harris P.L., Cash A.D., et al. Tau modifiers as therapeutic targets for Alzheimer's disease. Biochim Biophys Acta 1739 (2005) 211-215
36. Moreira P.I., Smith M.A., Zhu X., Nunomura A., Castellani R.J., and Perry G. Oxidative stress and neurodegeneration. Ann NY Acad Sci 1043 (2005) 545-552
37. 1 receptors. J Physiol Biochem 59 (2003) 263-268
38. Túnez I., Muñoz M.C., Feijóo M., Muñoz-Castañeda J.R., Bujalance I., Valdelvira M.E., et al. Protective melatonin effect on oxidative stress induced by okadaic acid into rat brain. J Pineal Res 34 (2003) 265-268
39. Túnez I., Drucker-Colín R., Muñoz M.C., and Montilla P. Cytoprotection by melatonin, precursors and metabolites in an in vitro model of neurotoxicity induced by okadaic acid. Lett Drug Design Discov 2 (2005) 316-321
40. Creppy E.E., Traore A., Baudrimont I., Cascante M., and Carratu M.R. Recent advances in the study of epigenetic effects induced by the phycotoxin okadaic acid. Toxicology 181-182 (2002) 433-439
41. Pérez M., Hernández F., Gómez-Ramos A., Smith M.A., Perry G., and Ávila J. Formation of aberrant phosphotau fibrillar polymers in neural cultured cells. Eur J Biochem 269 (2002) 1484-1489
42. Suuronen T., Kolehmainen P., and Salminen A. Protective effect of L-deprenyl against apoptosis induced by okadaic acid in cultured neuronal cells. Biochem Pharmacol 59 (2000) 1589-1595
43. Kaarniranta K., Ryhänen T., Sironen R.K., Suuronen T., Elo M.A., Karjalainen H.M., et al. Geldanamycin activates Hsp70 response and attenuates okadaic acid-induced cytotoxicity in human retinal pigment epithelial cells. Mol Brain Res 137 (2005) 126-131
44. Gimeno A., Zaragoza R., Viña J.R., and Miraller V.J. Vitamin E activates CRABP-II gene expression in cultured human fibroblasts, role of protein kinase C. FEBS Lett 569 (2004) 240-244
45. Levinthal D.J., and Defranco D.B. Reversible oxidation of ERK-directed protein phosphatases drives oxidative toxicity in neurons. J Biol Biochem 280 (2005) 5875-8583
46. Lysko P.G., Lysko K.A., Webb C.L., Feuerstein G., Mason P.E., Walter M.F., et al. Neuroprotective activities of carvedilol and a hydroxylated derivate. Biochem Pharmacol 56 (2005) 1645-1656